Testolift and tri-target testosterone support: what the in silico evidence actually means for you

Every few months a new supplement study circulates in men's health circles, and the question we get most often is some version of: "Is this one real?" A paper published in 2025 looked at a nutraceutical blend called Testolift and used computational modeling to predict how its ingredients might interact with three proteins involved in testosterone and muscle regulation -- aromatase, myostatin, and prolyl hydroxylase-2 (PHD2) (https://pubmed.ncbi.nlm.nih.gov/42277171/). The study is worth reading carefully. Not because it proves Testolift works, but because it gives us a useful framework for thinking about what these three biological targets actually do -- and what honest expectations look like when a supplement claims to affect them.

This post will walk through each target, explain what the evidence says about compounds that interact with it, and tell you plainly where the science is solid, where it is promising, and where it is still very early.

What the Testolift study actually did -- and did not do

The study used molecular docking and in silico (computer-based) modeling to test whether ingredients in the Testolift formulation could bind to three target proteins. Molecular docking is a legitimate early-stage research tool. Pharmaceutical companies use it to screen thousands of candidate molecules before deciding which ones are worth testing in cells, then animals, then humans.

The important limitation is built into the method itself. A compound that docks well to a protein in a simulation may do nothing meaningful when you swallow it. It has to survive digestion, reach the target tissue at a sufficient concentration, bind the protein in a living biological environment, and produce a downstream effect that is large enough to matter clinically. None of those steps were tested in this study. The authors are transparent about this -- they frame the findings as a basis for future research, not as proof of efficacy.

So when we talk about Testolift's three targets below, we are talking about the biology of the targets themselves and what the broader evidence base says about compounds that affect them -- not about whether this particular product delivers a clinical result. That distinction matters a great deal.

Target one: aromatase and estrogen conversion

Aromatase is an enzyme that converts testosterone into estradiol. That is a normal and necessary process -- men need some estradiol for bone density, cardiovascular health, and libido. Problems arise when aromatase activity is too high, which can occur in men who carry excess body fat (adipose tissue is a major site of aromatase expression). When too much testosterone converts to estradiol, you can end up with both low testosterone and elevated estrogen, which compounds the symptom picture.

Prescription aromatase inhibitors -- anastrozole and letrozole are the most common -- are sometimes used off-label in men with secondary hypogonadism and confirmed high estradiol. The Endocrine Society guideline notes this use while also flagging that the evidence base for aromatase inhibitor monotherapy in men is smaller than for testosterone replacement therapy (TRT) (https://pubmed.ncbi.nlm.nih.gov/29562364/). The AUA guideline on testosterone deficiency similarly calls for confirmed lab values before any treatment is initiated (https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline).

Some plant-derived compounds -- certain flavonoids, chrysin, and components of herbs like Eurycoma longifolia -- have shown aromatase-inhibiting activity in laboratory settings. The Testolift paper tests ingredients along these lines computationally. Whether any of them inhibit aromatase enough, in enough men, at oral doses that survive the gut, to produce a measurable change in testosterone or estradiol is a question that requires a randomized controlled trial. That trial does not yet exist for this formulation.

If you are gaining weight in the midsection, have confirmed low testosterone, and your estradiol is elevated on a morning blood draw, that is a clinical situation worth addressing -- under supervision, with monitoring. It is not a situation best handled by a supplement bought online.

Target two: myostatin and muscle mass

Myostatin is one of the more fascinating targets in exercise and muscle biology. It is a protein produced by muscle tissue that limits how large muscles can grow -- essentially a brake on hypertrophy. Animals with naturally occurring myostatin deficiencies or with myostatin knocked out genetically develop dramatically larger muscles. The "double-muscled" cattle breeds you may have seen in photographs are a real-world example of what happens when this brake is removed (https://pubmed.ncbi.nlm.nih.gov/19424046/).

The pharmaceutical industry has been working on myostatin inhibitors for years, primarily for muscle-wasting diseases like Duchenne muscular dystrophy and sarcopenia. Some of those trials have produced modest results; none have produced results as dramatic as the animal data. Human muscle biology is more complicated, and orally bioavailable myostatin inhibitors that produce clinically meaningful hypertrophy in healthy adults have not been established.

Nutraceutical ingredients that have been studied for myostatin-related effects include epicatechin (found in dark chocolate and green tea) and certain urso derivatives. The in vitro and animal data are genuinely interesting. The human clinical trial data -- in terms of actual muscle mass gain from supplementation -- is much thinner.

The Testolift paper identifies binding predictions for some of its ingredients at the myostatin target. That is a reasonable hypothesis to generate. It is several research steps away from a clinical recommendation.

For context: the most robustly evidenced intervention for preserving and building muscle in men over 35 remains progressive resistance training, adequate dietary protein (roughly 1.6 to 2.2 grams per kilogram of body weight per day by most evidence summaries), and where clinically indicated, TRT combined with exercise -- which our earlier post on testosterone replacement therapy combined with exercise and body composition covers in detail.

Target three: prolyl hydroxylase-2 (PHD2) and oxygen sensing

PHD2 is the least familiar of the three targets to most readers, and arguably the most mechanistically interesting. PHD2 is an enzyme that regulates hypoxia-inducible factor 1-alpha (HIF-1α) -- a protein that acts as a master switch for the body's response to low oxygen. When oxygen is plentiful, PHD2 degrades HIF-1α. When oxygen is low (during intense exercise, for example, or at altitude), PHD2 activity drops, HIF-1α rises, and a cascade of adaptations follows: increased red blood cell production, changes in energy metabolism, and potentially effects on steroidogenesis -- the pathway that produces testosterone.

The link between HIF-1α and testosterone biosynthesis is an active area of basic science research (https://pubmed.ncbi.nlm.nih.gov/26926106/). The idea that a nutraceutical ingredient could modestly inhibit PHD2, raise HIF-1α, and thereby support testosterone production is biologically plausible at the hypothesis level. It is not established in clinical trials.

PHD2 inhibition is also the mechanism behind a class of drugs called HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors) -- roxadustat is one example -- which are used for anemia of chronic kidney disease. These are prescription drugs with real side-effect profiles, not analogous to a supplement claiming the same mechanism at a consumer dose.

What reversible causes you should rule out first

Before any supplement or even TRT conversation makes sense, it is worth asking why testosterone might be low in the first place. Some of the most common causes are entirely reversible, and treating the cause is preferable to supplementing around it.

Untreated obstructive sleep apnea is one of the most underappreciated suppressors of testosterone. One well-designed study found that one week of sleep restriction dropped testosterone levels by 10 to 15 percent in healthy young men (https://pubmed.ncbi.nlm.nih.gov/21632481/). Excess adipose tissue drives aromatase activity and suppresses hypothalamic signaling -- weight loss alone can meaningfully raise testosterone in men with obesity-related hypogonadism (https://pubmed.ncbi.nlm.nih.gov/25668680/). Vitamin D deficiency has been associated with lower testosterone in some studies, with one randomized trial showing a modest rise with supplementation (https://pubmed.ncbi.nlm.nih.gov/21154195/). Chronic opioid use, certain antidepressants, and anabolic steroid use all suppress the HPG axis and must be addressed before any testosterone treatment is layered on.

None of these reversible causes are fixed by a nutraceutical targeting aromatase, myostatin, or PHD2. They require a real clinical workup.

If you are curious about where your baseline sits and what might be driving symptoms, our post on signs of low testosterone walks through what clinicians look for and what symptoms actually belong on that diagnostic list.

How we think about nutraceuticals at NoMi Beach Health

We are not reflexively against supplements. Some have a legitimate supporting role in a well-designed protocol. Vitamin D in deficient men, zinc in men with documented deficiency, and creatine monohydrate for resistance-trained adults all have reasonable evidence bases. We use them where the data supports it.

What we will not do is position a supplement as a substitute for a diagnosis. If you are tired, your muscle is thinning, your libido has dropped, and your morning erections have changed -- those are symptoms that belong on a lab requisition, not in a supplement shopping cart. The AUA standard is two morning total testosterone draws below 300 ng/dL, paired with symptoms, before treatment is initiated (https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline). We follow that standard.

The Testolift paper is interesting science at an early stage. The three targets it identifies -- aromatase, myostatin, and PHD2 -- are genuinely relevant to testosterone regulation and muscle performance. The computational predictions are hypothesis-generating, not outcome-proving. We will watch for the clinical trials that should follow. Until those exist, we cannot recommend this formulation as a treatment for hypogonadism or muscle loss.

If you are navigating this space -- wondering whether your symptoms reflect low testosterone, asking whether a supplement fits your situation, or wanting to understand your labs -- that is exactly the kind of conversation our men's health program is built for. We draw the right labs, ask the right questions, and tell you what the evidence actually supports. You can also read more about what a complete men's health evaluation looks like in our concierge men's health after 35 guide.

Book a new-patient visit online or call us at (786) 744-5152. Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) will review your labs, talk through your goals, and give you a clear picture of what is driving what -- without the supplement-industry noise.